HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe
Shots:
- HUTCHMED to receive a $10M milestone payment by Takeda after gaining a national reimbursement recommendation for Fruzaqla (fruquintinib) for formerly treated metastatic colorectal cancer in Spain
- In Jun’24, Fruzaqla was approved by the EC based on the results of the P-III (FRESCO-2) study. Furthermore, Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong, and Macau
- Fruquintinib selectively inhibits all three VEGF receptors (VEGFR-1, -2, and -3), ultimately inhibiting tumor angiogenesis
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
